| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/31/2001 | CN1282254A Compositions and methods for regulating phagocytosis and ICAM-1 expression |
| 01/31/2001 | CN1282253A Small peptides and method for treatment of asthma and inflammation |
| 01/31/2001 | CN1282252A Ginkgo biloba leaf extracts with reduced 4'-0-methylpyridoxine and biflavone content |
| 01/31/2001 | CN1282248A Combination effective for treatment of impotence |
| 01/31/2001 | CN1282245A Molecular dispersion composition with enhanced bioavailability |
| 01/31/2001 | CN1282244A Pharmaceutical compositions |
| 01/31/2001 | CN1282242A Multicatalytic protease inhibitors for use as anti-tumor agents |
| 01/31/2001 | CN1281852A 三唑及咪唑衍生物 Triazole and imidazole derivatives |
| 01/31/2001 | CN1281717A Health-care product for removing toxic material and delaying senility and its preparation method |
| 01/31/2001 | CN1281694A Composite for oxidation-dyeing keratin fibre and its dyeing method |
| 01/31/2001 | CN1061341C 1-amino-ethylindole-derivatives |
| 01/31/2001 | CN1061254C Medicine mixed type cigarette and producing method thereof |
| 01/30/2001 | US6180764 Process for producing hydrotalcites by hydrolyzing metal alcoholates |
| 01/30/2001 | US6180681 2-cyclopenten-1-one as an inducer of HSP70 |
| 01/30/2001 | US6180680 Cardiovascular disorders |
| 01/30/2001 | US6180676 Guanylhydrazones and their use to treat inflammatory conditions |
| 01/30/2001 | US6180671 Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected |
| 01/30/2001 | US6180665 Crystalline polymorphic form of (S,S,S)-N-(1-[2-carboxy-3 (N2-mesyllyslamino) propyl]-1- cyclopentylcarbonyl) tyrosine |
| 01/30/2001 | US6180662 Mixture of cinnamic acid, antioxidant, enzyme, microbiocides and viricides |
| 01/30/2001 | US6180657 Melatonin derivatives for use in treating desynchronization disorders |
| 01/30/2001 | US6180654 Heterocyclic nonnucleoside inhibitors of reverse transcriptase |
| 01/30/2001 | US6180650 Antiinflammatory agents; respiratory system disorders; skin disorders; antitumor agents |
| 01/30/2001 | US6180647 Gastrointestinal disorders; nervous system disorders |
| 01/30/2001 | US6180644 Immunotherapeutic agents |
| 01/30/2001 | US6180637 Therapy for parkinson, alzheimer disease |
| 01/30/2001 | US6180636 Substituted pyrrolopyrimidines and processes for their preparation |
| 01/30/2001 | US6180635 Novel thieno(2,3-d)pyrimidinediones which exhibit pharmacological activity, in particular immunosuppressive activity; treating allograft rejection |
| 01/30/2001 | US6180632 Use of these compounds for treating disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or t cell activation and proliferation |
| 01/30/2001 | US6180631 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds |
| 01/30/2001 | US6180630 Tricyclic pyrazolo-pyridazinone analogues as GAGA-A receptor ligands |
| 01/30/2001 | US6180620 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| 01/30/2001 | US6180619 Prenyl transferase inhibitors |
| 01/30/2001 | US6180615 Propargyl phenyl ether A2A receptor agonists |
| 01/30/2001 | US6180611 Inhibitors of matrix metalloproteinases and tumor necrosis factor |
| 01/30/2001 | US6180403 Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression |
| 01/30/2001 | US6180386 DNA sequences coding for the human proteins Tx and Ty related to the interleukin-1beta converting enzyme |
| 01/30/2001 | US6180371 Modified factor VIII |
| 01/30/2001 | US6180355 Method for diagnosing and treating chronic pelvic pain syndrome |
| 01/30/2001 | US6180104 Can be used such as nucleotide probes, combining with foreign dna sequences to produce novel t-cell receptors, which can be used in an analogous manner as antibodies, or constructs can be provided which provide for extrachromosomal elements |
| 01/30/2001 | US6180095 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| 01/30/2001 | CA2313825A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/30/2001 | CA2238098C Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis |
| 01/30/2001 | CA2191352C Quinoline derivatives as tachykinin nk3 receptor antagonists |
| 01/30/2001 | CA2064558C Method for inhibiting growth of stem cells |
| 01/30/2001 | CA2056997C A human cytokine, interleukin-9 |
| 01/29/2001 | CA2314682A1 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 01/25/2001 | WO2001006756A2 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 01/25/2001 | WO2001006261A2 Screening for therapeutic agents being scap antagonists |
| 01/25/2001 | WO2001006015A1 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 01/25/2001 | WO2001006010A1 Antisense modulation of telomeric repeat binding factor 1 expression |
| 01/25/2001 | WO2001005983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | WO2001005972A1 Compositions and methods for the treatment of immune related diseases |
| 01/25/2001 | WO2001005970A2 Gtp-binding protein associated factors |
| 01/25/2001 | WO2001005969A2 Electron transfer proteins |
| 01/25/2001 | WO2001005968A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 01/25/2001 | WO2001005958A1 Antisense modulation of p13 kinase p110 delta expression |
| 01/25/2001 | WO2001005954A1 Antisense modulation of liver glycogen phosphorylase expression |
| 01/25/2001 | WO2001005947A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | WO2001005944A1 Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell |
| 01/25/2001 | WO2001005940A2 Methods for producing and preparing cells for cell therapy |
| 01/25/2001 | WO2001005833A1 Odorant receptors |
| 01/25/2001 | WO2001005826A2 Chimeric polypeptides of serum albumin and uses related thereto |
| 01/25/2001 | WO2001005823A2 Tryptase inhibitor |
| 01/25/2001 | WO2001005820A2 Method for down-regulating gdf-8 activity |
| 01/25/2001 | WO2001005810A2 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN αVβ¿6? |
| 01/25/2001 | WO2001005802A1 Antisense modulation of fadd expression |
| 01/25/2001 | WO2001005790A1 New compounds |
| 01/25/2001 | WO2001005784A1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR Xa INHIBITORS |
| 01/25/2001 | WO2001005783A1 Bradykinin b1 receptor antagonists |
| 01/25/2001 | WO2001005782A1 Novel diphenyl-piperidine derivate |
| 01/25/2001 | WO2001005776A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 01/25/2001 | WO2001005773A1 Conjugates of sodium channel blockers and methods of using the same |
| 01/25/2001 | WO2001005772A1 Pyrazinones, compositions containing such compounds |
| 01/25/2001 | WO2001005771A1 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists |
| 01/25/2001 | WO2001005770A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 01/25/2001 | WO2001005765A1 Cyclic amides and imides having selective antagonist activity at alpha-1d adrenergic receptor |
| 01/25/2001 | WO2001005764A2 Sulfuric acid mono-[3-({1- [2-(4-fluoro-phenyl)-ethyl]- piperidin-4-yl}- hydroxy- methyl)-2- methoxy-phenyl]ester |
| 01/25/2001 | WO2001005761A1 sPLA2 INHIBITORS |
| 01/25/2001 | WO2001005758A2 Indoles and indazoles for the treatment of migraine |
| 01/25/2001 | WO2001005756A1 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors |
| 01/25/2001 | WO2001005749A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005746A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005744A1 Novel aminobenzophenones |
| 01/25/2001 | WO2001005742A1 Quaternary bis-ammonium salt precursors and their uses as prodrugs having an antiparasitic activity |
| 01/25/2001 | WO2001005430A1 Sustained release drug dispersion delivery device |
| 01/25/2001 | WO2001005428A1 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 01/25/2001 | WO2001005422A2 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | WO2001005420A1 Small peptides and methods for downregulation of ige |
| 01/25/2001 | WO2001005418A2 Tissue regenerating agent |
| 01/25/2001 | WO2001005414A1 Algae protein polysaccharide extraction and use thereof |
| 01/25/2001 | WO2001005404A1 Use of beta-napthoquinone for making medicines having an inhibiting effect on the release of glutamate by the brain |
| 01/25/2001 | WO2001005398A1 Phosphate transport inhibitors |
| 01/25/2001 | WO2001005397A1 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same |
| 01/25/2001 | WO2001005393A2 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | WO2001005392A2 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | WO2001005390A2 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | WO2001005388A2 Use of a fatty derivative for the treatment of external secretiondisorders |
| 01/25/2001 | WO2001005383A2 Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine |
| 01/25/2001 | WO2001005382A1 Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds |
| 01/25/2001 | WO2001005368A1 Use of at least one extract of a plant of the genus lannea in a cosmetic or dermopharmaceutical composition |